Welcome to our Press Archive section below you will find Archive stories and posts and all types of information from the past. Please feel free to browse and enjoy.
- All
- Ad-hoc
- Finance
- Innovation
- Leadership
- Press

02Jan2023
New Site Manager at Bachem Headquarters: Meet Frank Dettner
We are pleased to announce that Frank Dettner will take on the role of Site Manager in Bubendorf (Ba...

16Dec2022
Bachem signs long-term follow-on contract for peptides
Contract signed with a total minimum order volume of CHF 1 billion over a five-year period from 2025...

14Nov2022
Bachem Welcomes New Site Manager in Torrance: Luckner Ulysse
We are pleased to announce that Luckner Ulysse will take on the role of Site Manager in Torrance (US...

05Oct2022
Bachem expands presence in northwestern Switzerland. New production site planned in Sisslerfeld.
The third Bachem site in Switzerland will be built in Sisslerfeld in the municipality of Eiken (cant...

20Sep2022
Bachem signs large volume contracts for peptides
Two contracts signed with order volumes of CHF 25 million in 2023 and CHF 150 million in 2024....

09Sep2022
CHANGE TO THE IT LEADERSHIP
We are pleased to announce the appointment of a new Global CIO. ...

25Aug2022
Bachem with slight decline in sales to CHF 234.9 million in the first half of 2022. Strong growth expected in the second half of the year.
Strong growth expected in the second half of the year....

05Aug2022
Addition to the Bachem leadership team
We are pleased to announce the appointment of a new Global Head of HR / Chief Human Resources Office...

11Jul2022
Bachem’s Journey to Industry 4.0
Bachem has started its journey to industry 4.0 and has reached a new level of automation and digital...

11May2022
Innovation transforming oligonucleotide manufacturing
Bachem set up unique, innovative equipment that optimizes capacity, delivers high-quality products a...

27Apr2022
Bachem Annual General Meeting 2022
The Annual General Meeting (AGM) 2022 has approved all proposals of the Board of Directors...

26Apr2022
Entering strategic collaboration with Lilly to manufacture oligo-based drug substances
The annual order volume has the potential to achieve around CHF 100 million....
Contact us